2-Amino-N-Phenethylbenzamides用于刺激性肠综合征的治疗
Miglena Milusheva1,2, Mihaela Stoyanova1, Vera Gledacheva3
1Department of Organic Chemistry, Faculty of Chemistry, University of Plovdiv, 4000 Plovdiv, Bulgaria.
Molecules (Basel, Switzerland)
|July 27, 2024
概括
新的抗性化合物被合成用于刺激性肠综合征 (IBS) 治疗. 这些新型药物表现出类似于mebeverine的放松作用,但潜在的副作用较少,并增加了抗炎作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 胃肠病学 胃肠病学
背景情况:
- 刺激性肠综合征 (IBS) 是一种普遍的胃肠道疾病,导致腹部疼痛.
- 梅贝维林是IBS常见的抗药,但系统性使用可能会引起副作用.
- 需要更有效,更安全的IBS治疗方法.
研究的目的:
- 合成用于IBS治疗的新型化合物.
- 评估新合成的2-氨基-N-乙胺基的抗和抗炎活性.
- 研究这些化合物的作用机制.
主要方法:
- 通过异酸无水化物的环开放合成2-amino-N-phenethylbenzamides.
- 在状体内预测解活动.
- 在体外和体外测试抗炎作用和对信号通路的影响.
- 评估介素-1β表达和神经元氧化合成酶 (nNOS) 活性.
主要成果:
- 合成的化合物显示了可比于mebeverine的解活性.
- 化合物没有干扰血清素或Ca2+依赖的信号通路.
- 四种化合物表现出显著的抗炎作用,抑制了白蛋白变性.
- 观察到抑制互白素-1β和刺激nNOS/氧化 (NO) 合成.
结论:
- 合成的2-amino-N-phenethylbenzamides是强大的生物活性放松剂,具有抗炎性质.
- 与现有治疗方法相比,这些化合物具有潜在的更清洁的药理特征.
- 这些新型化合物代表了增强IBS治疗的有希望的候选者.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
01:21Drugs for Treatment of Constipation-Predominant IBS
151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
236
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
236
01:29Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
154
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
154
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
189
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
189